EdiPro Pharmaceutical
Latest round
- Angel
Last raised
- May 2022
Total raised
- Undisclosed
Investors
- 1
About EdiPro Pharmaceutical
, dba EdiPro Pharmaceutical, is dedicated to building an innovative drug platform that develops novel therapeutics for major diseases and rare genetic disorders. The company was founded by Dr. Shixian Lin, a professor and doctoral supervisor at the Institute of Life Sciences, Zhejiang University. EdiPro Pharmaceutical focuses on the development of long-acting peptides, cyclic peptides and antibody-peptide conjugates. leveraging a synthetic biology platform powered by its self-developed chimeric translation system, targeting major chronic metabolic diseases, as well as genetic diseases caused by nonsense mutations. The company generates revenue from developing novel peptide and protein-based drugs.
Who invested in EdiPro Pharmaceutical
1 investor across 1 round
See all investors in EdiPro Pharmaceutical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
May 24, 2022
Amount
Undisclosed
Investors
Questions about EdiPro Pharmaceutical
Who invested in EdiPro Pharmaceutical?
EdiPro Pharmaceutical has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EdiPro Pharmaceutical raised?
EdiPro Pharmaceutical has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did EdiPro Pharmaceutical last raise money?
EdiPro Pharmaceutical's most recent round on record is a Angel, in May 2022.
What does EdiPro Pharmaceutical do?
, dba EdiPro Pharmaceutical, is dedicated to building an innovative drug platform that develops novel therapeutics for major diseases and rare genetic disorders.
Where is EdiPro Pharmaceutical headquartered?
EdiPro Pharmaceutical is headquartered in Chengdu, China.
Which VCs invest in companies like EdiPro Pharmaceutical?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back companies at EdiPro Pharmaceutical's stage. Their profiles are linked below.
VCs to look at next
Raising like EdiPro Pharmaceutical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.